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Objective-To assess the efficacy of a short
course chemotherapy regimen for treating tubercu-
losis of the lymph nodes in children.
Design-Open, collaborative, outpatient clinical
trial.
Setting-Outpatient department of the Tubercu-
losis Research Centre, paediatric surgery depart-
ments of the Institute of Child Health and Hospital
for Children and the Government Stanley Hospital,
Madras, South India.
Patients-Children aged 1-12 years with extensive,
multiple site, superficial tuberculous lymphadenitis
confirmed by biopsy (histopathology or culture).
Interventions-Patients were treated with a fully
supervised intermittent chemotherapy regimen
consisting of streptomycin, rifampicin, isoniazid,
and pyrazinamide three times a week for two months
followed by streptomycin and isoniazid twice a week
for four months on an outpatient basis. Surgery
was limited to biopsy of nodes for diagnosis and
assessment.
Main outcome measures-Response to chemo-
therapy was assessed by regression of lymph nodes
and healing of sinuses and abscesses during treat-
ment and follow up. Compliance with treatment and
frequency of adverse reactions were also estimated.
Results- 197 Patients were admitted to the study
and 168 into the analysis. The regimen was well
tolerated and compliance was good with 101 (60%)
patients receiving the prescribed chemotherapy
within 15 days of the stipulated period of six months.
Those whose chemotherapy extended beyond that
period received the same total number of doses.
Clinical response was favourable in most patients at
the end of treatment. Sinuses and abscesses healed
rapidly. Residual lymphadenopathy (exceeding 10
mm diameter) was present in 50 (30%) patients at the
end of treatment; these nodes were biopsied. Fresh
nodes, increase in size of nodes, and sinuses and
abscesses occurred both during treatment and
follow up. After 36 months of follow up after
treatment only 5 (3%) patients required retreatment
for tuberculosis.
Conclusion-Tuberculous lymphadenitis in
children can be successfully treated with a short
course chemotherapy regimen of six months.
Introduction
Tuberculous lymphadenitis is the commonest
extrapulmonary manifestation of tuberculosis. 2 Short
course chemotherapy is now well established in treating
pulmonary tuberculosis,3'4 but there is little information
about its value in lymph node disease in children. In a
controlled clinical trial in Britain the British Thoracic
Society found that a nine month regimen of rifampicin
and isoniazid supplemented by ethambutol for the first
two months was as effective as a conventional 18 month
regimen in adults with tuberculous lymphadenitis,56
and McCarthy and Rudd have reported the success
of a six month regimen.7 Previous reports on
the management of this disorder had dealt with
conventional regimens of longer duration with or
without surgery.8'0 All these studies were of adults.
We report our experience with an intermittent six
month regimen for treating children with predominantly
multiple site, extensive, and severe lymphadenitis in
Madras, South India, including the findings during 36
months of follow up after stopping treatment.
Patients and methods
The study was conducted at the Tuberculosis
Research Centre, Madras (Indian Council of Medical
Research) in collaboration with the paediatric surgery
departments of the Institute of Child Health and
Hospital for Children and the Government Stanley
Hospital. Children aged 1-12 living in or near Madras
with tuberculosis of the lymph nodes proved by biopsy
(by histopathological examination or culture) were
eligible for admission to the study. Those with renal,
hepatic, or haematological disease or who had pre-
viously received more than one month of treatment for
tuberculosis were not eligible.
PRETREATMENT ASSESSMENT AND INVESTIGATIONS
Children with a clinical diagnosis of tuberculous
lymphadenitis were assessed initially by a paediatric
surgeon, who performed a biopsy of the most
prominent lymph node under general anaesthesia.
Serial sections of the node were examined by an
independent pathologist. Bacteriological investigations
consisted of examination of a smear by fluorescence
microscopy and culture of the node for tubercle bacilli
using multiple media (Lowenstein-Jensen medium,
Lowenstein-Jensen medium with sodium pyruvate,
7-hydroxy-1 1 oleic acid albumin medium, and liquid
Kirchner's medium). " Growth ofMycobacterium tuber-
culosis in any one medium was considered diagnostic
for tuberculosis. Positive cultures were identified and
drug sensitivity tests were carried out using standard
procedures. 12
Patients were admitted to the study if histological
examination of the lymph node suggested tuberculosis.
Patients whose node yieldedM tuberculosis on culture,
but in whom histological examination of the node was
negative were also admitted. All patients had a postero-
anterior radiograph of the chest; a smear and culture
for M tuberculosis from sputum if the radiograph was
abnormal, and from any sinus discharge; a Mantoux
test with 1 tuberculin unit purified protein derivative
RT23 with Tween 80; and examination of urine for
albumin, sugar, urobilinogen, and acetylisoniazid.
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SHORT COURSE CHEMOTHERAPY REGIMEN
Patients were treated with a fully supervised inter-
mittent regimen of six months' duration, consisting of
streptomycin (40 mg/kg body weight; maximum dose
750 mg), rifampicin (as syrup, 10 mg/kg), isoniazid (15
mg/kg), and pyrazinamide (45 mg/kg) three times a
week for two months followed by streptomycin and
isoniazid twice a week for the next four months. A
dosage schedule-with 5 kg weight interval was used.
Patients received the drugs as a single dose under
supervision on an outpatient basis.
Missed doses were compensated so that a patient
received 26 doses of the first phase (four drugs) within
three months and 36 doses of the continuation phase
(two drugs) within six months. Thus the maximum
duration of treatment was nine months.
ASSESSMENT DURING TREATMENT AND FOLLOW UP
Clinical progress was monitored every month by a
physician at the Tuberculosis Research Centre and by
the paediatric surgeon at one, three, and six months
and, if chemotherapy was prolonged beyond six
months, at the end of treatment also. Radiography of
the chest and sputum examinations were repeated at
one, two, and six months if initially they had shown
abnormal results. A specimen of urine was examined
monthly for acetylisoniazid.
At the completion of treatment the surgeon had the
option to repeat the lymph node biopsy if residual
lymphadenopathy of more than 10 mm diameter was
present. Histological and bacteriological examinations
were done on these biopsy specimens. In the follow up
period the patients were examined monthly up to 12
months, three monthly up to 24 months, and every six
months thereafter.


































TABLE II-Incidence of new nodes, enlargement of existing nodes, and neuw sinuses a'
treatment by short course chemotherapy of 168 children with tuberculous lymphadenitis
Month of occurrence
No of No of
patients episodes 1 2 3 4 5 6
New nodes or enlargement of nodes 32* 36 14 t 11 t t 11
Sinuses 10 10 6t 1 1 2
Abscesses 4 6 3 2 1
*28 Patients had one episode each and four patients had two episodes each; assessment for lymph node enlargement
was done at 1, 3, and 6 months.
tNot assessed.
iFour of these patients had abscesses on admission.
Results
Intake to the study was from February 1980 to
September 1985. Of the 197 patients admitted to the
study, 29 were excluded from analysis (because of
ineligibility for admission to study (16), isolation of
atypical mycobacteria (M terrae complex-probably
contaminants) on lymph node culture (6), defaulting
before completing treatment (3), drug toxicity (2), and
loss to follow up after treatment (2)). This report
presents the findings in 168 patients who were followed
up for 36 months after completing treatment.
Table I shows the pretreatment characteristics of the
study population. In all, 96 patients had positive
lymph node cultures, including four in whom the
results on histopathological examination of the node
were negative. Of the positive cultures, 18 (19%) were
resistant to one or more drugs: two to streptomycin, 10
to isoniazid, and six to both; none was resistant to
rifampicin.
Multiple, extensive lymph node involvement was
common. The mean number of node groups per
patient was 2-8. In only 40 (24%) patients was a single
group of nodes affected, in 48 (29%) two groups, in 11
(7%) three, in 53 (32%) four, and in 16 (10%) five or
more groups were affected. In 59 (35%) patients only
cervical nodes were affected, in 10 (6%) only axillary
nodes, and in 13 (8%) only inguinal nodes. Sixty five
(39%) patients had a combination of cervical and
axillary lymphadenitis, and in 18 (11%) all three
groups of nodes were affected. Three patients had
adenitis at other sites (epitrochlear (two) and femoral
(one)). Fourteen patients had sinuses, 26 had abscesses,
and 23 had both.
TREATMENT
In all, 101 (60%) patients had completed the chemo-
ren with tuberculous therapy within six months and 15 days. A further 32
(19%) had chemotherapy extended up to seven months,
26 (15%) up to eight months, and nine (5%) up to nine
No (%) of patients months to compensate for missed doses.
All 168 patients improved clinically with treatment.
85(51) Lymph nodes became smaller, though they did not
83 (49) always become impalpable. Sinuses and abscesses
78 (46) healed rapidly: of the 63 lesions, 51 (81%) resolved by
41(24) one month of treatment, 60 (95%) by three months,49 (29) and all by the end of treatment. During treatment,
nodes enlarged or fresh nodes appeared in 32 patients
14(8) (36 episodes), and fresh sinuses and abscesses occurred7(4) (3 frs
40(24) in 10 and four patients respectively (table II). One
107 (64) patient developed abscesses on three occasions.
17(10) At the end of treatment 50 (30%) patients had
6(4) residual lymphadenopathy (>10 mm), for which repeat16(10) biopsy was carried out. Of these, 41 biopsies were10(6)
119 (71) histologically and bacteriologically negative. Two
96 patients had positive culture forM tuberculosis (one also
U}(62) had positive results on histological examination); both
6
60 cultures were fully sensitive to streptomycin, isoniazid,
101 38) and rifampicin. Both patients were retreated for
°;( )12 tuberculosis. M scrofulaceum was isolated in one
patient who was not treated again as she had only a
164 (98) single residual node which was removed at biopsy and
4(2) she had no symptoms. Six patients with positive results
only on histological examination were not treated. One
nd abscesses during of them developed a cold abscess two months later and
was then retreated.
FOLLOW UP
All the patients were followed up for 42 months from
the start of treatment (33-36 months after treatment).
Enlargement of nodes and appearance of new nodes,
sinuses, and abscesses occurred in this period (table
III). Six patients were subjected to further biopsies to
exclude relapse: one at five months, another at seven
months, two at nine months, and two more at 24
months after stopping treatment. All the biopsies were
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patients 7 8 9 12 15 18 21 24 30 36 42
New nodes or enlargement of nodes 26* t t 10 4 8 5 6 2 3 1
Sinuses 5 2 2 1
Abscesses 7- 1t 1 2 1 1 1
Mesenteric adenitis 1 1
Tuberculous meningitis 1 1
* 19 Patients had one episode, three patients had two, three had three, and one had five episodes; total 39 episodes.
tNot assessed.
tCervical cold abscess; retreated for tuberculosis.
negative histologically and bacteriologically. Sinuses
that appeared also healed with a course of ampicillin or
co-trimoxazole. One patient developed mesenteric
lymphadenitis four months after stopping treatment
and another tuberculous meningitis 35 months after
stopping treatment.
In all, five (3%) patients required retreatment for
tuberculosis after completing the study regimen, two
because of a positive node culture at the end of
treatment, one for a cervical cold abscess, another for
mesenteric lymphadenitis, and the last for tuberculous
meningitis. In all five patients pretreatment
culture had yielded organisms sensitive to strepto-
mycin, isoniazid, and rifampicin.
ADVERSE REACTIONS TO DRUGS
In all, 178 patients completed treatment, including
10 patients not included in the main analysis: six who
were not eligible for admission to the study, two lost to
follow up, and two in whom streptomycin was toxic,
for which the regimen was changed. Reactions possibly
attributable to drugs were observed in 13 other
patients; most were mild. Four patients had giddiness
due to streptomycin so the dosage was reduced. Two
patients developed jaundice; treatment was withheld
temporarily and resumed uneventfully once the
jaundice had subsided. Four patients had gastro-
intestinal symptoms and three pruritus; these symptoms
responded to treatment.
Discussion
A striking feature of this study was the severity with
which lymph nodes were affected. Multiple sites were
very common, and in 69 (41%) patients four or more
groups of nodes were affected. Cervical and axillary
adenitis occurred together in 65 (39%) and cervical
adenitis alone in 59 (35%) patients, and all three groups
of nodes (cervical, axillary, and inguinal) were affected
in 18 (11%) patients. Advanced lesions with sinuses
or abscesses, or both, were seen in 63 (38%) of
the 168 patients, a much higher figure than reported
previously.9 13
The overall bacteriological positivity rate (smear and
culture) from the lymph node biopsy specimens was
68%. This compares favourably with the figures
reported in other studies, which have ranged from 30-
55%.9 '3 '4 We used multiple culture media as recom-
mended by Mitchison et al."
Clinical response to- treatment was favourable in
most patients, with regression in the size of lymph
nodes and prompt healing of sinuses and abscesses.
The rapidity with which sinuses and abscesses resolved
was particularly striking, 51 (81%) of these lesions
having disappeared within one month of the start of
treatment. Although lymph nodes became smaller,
they did not always become impalpable. At the end of
treatment, 50 (30%) patients had one or more residual
nodes exceeding 10mm diameter. This is considerably
higher than the 9% and 13% reported in the two earlier
British studies"9 and is not surprising considering the
extensive and severe type of disease seen in our
population.
Both the chemotherapy and the follow up periods
were punctuated by events such as enlargement of
nodes and appearance of new nodes and of sinuses and
abscesses in some patients. These events occurred
relatively more frequently in the early months of
chemotherapy and follow up and less often later. These
episodes almost always resolved spontaneously or after
a course of ampicillin or co-trimoxazole and did not
presage a relapse. Similar observations have been
documented by the British Thoracic Society study and
by Campbell and Dyson."9 These transient events may
be the result of cellular reaction to the products of
disintegration of the bacilli, probably to their cell wall
components.'0'5 Further, histological changes in the
nodes may take a number of months to regress, as
evidenced by the fact that six patients still had
histological evidence of tuberculosis in the lymph node
with negative cultures at the end of treatment.
In all, five (3%) patients received additional chemo-
therapy for tuberculosis after completing the prescribed
regimen. In two this was because they had positive
lymph node cultures at the end of treatment, evidence
that the regimen had not sterilised the nodes. Two
patients had episodes of lymphadenitis (one cervical
and one mesenteric) and another developed meningitis
35 months after stopping treatment.
The regimen was well tolerated. Apart from two
patients who required a change of regimen for strepto-
mycin toxicity (these patients were excluded from
this analysis), only minor adverse reactions were
experienced and treatment could be continued un-
interrupted in most of the patients.
In conclusion, this study shows that a short course
regimen of six months is effective in treating severe
forms of lymph node tuberculosis in children. At the
end of 36 months of follow up after treatment, the
outcome was satisfactory in 163 (97%) of the 168
patients. Increase in the size of nodes and appearance
of new nodes, sinuses, and abscesses were seen
during both treatment and follow up. These were
usually transient events and did not suggest a relapse.
Surgery was seldom indicated except for diagnosis and
for draining lymph node abscesses in a few patients.
The patients are being followed up further and will
be reported on after five years of follow up.
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Symptoms of low blood pressure: a population study
Simon Wessely, Judith Nickson, Brian Cox
Abstract
Objective-To establish whether an association
exists between blood pressures in the "low normal"
range and common symptoms such as tiredness,
dizziness, headache, and palpitation, as suggested
by French and German medical practice but not
English or American medical practice.
Design-Cross sectional population based survey
(the health and lifestyle survey) of blood pressure
measurements and selfreported common symptoms.
Results were analysed by combined stratification
and logistic regression.
Subjects-7383 (82%) Adults aged 18 and over
chosen from the electoral register in England, Wales,
and Scotland for the health and lifestyle survey, in
whom satisfactory physiological measurements were
taken, from 9003 in the interviewed sample.
Main outcome measures-Body mass index,
smoking, social class, exercise, selfdeclared physical
illnesses, hours slept, use ofdrugs, and psychological
illness as determined with the general health
questionnaire assessed as potential confounders.
Results-True confounders were sex, age, taking
of drugs, physical illness, exercise, and body mass
index. A negative association was found between
systolic blood pressure and self reported tiredness
and feeling faint, which persisted after adjustment
for the confounders. The association was strongest
in women aged under 50. A negative association
between systolic blood pressure and headache and a
positive association between systolic blood pressure
and palpitation were explained by confounding by
age.
Conclusions -Systemic hypotension is associated
with persistent tiredness but treatment is not
suggested as either possible or necessary. Instead,
low blood pressures may be associated with opposite
effects on mortality contrasted with morbidity.
Introduction
In the United Kingdom systolic blood pressures in
the "low normal" range are regarded as desirable
whereas in West Germany they are seen as pathological
and are treated with antihypotensive drugs such as
digoxin and ergotamine, as well as with numerous
physical treatments. ' 2 Cardiac glycosides are the
second most common prescription drugs in West
Germany.3 Similar cross cultural differences have been
confirmed in several other European countries.24 In
the United States and Canada the academic consensus
follows the British model in believing that "constitu-
tional" hypotension is a spurious disease entity, and
the concept is either dismissed or ignored in all the
current leading medical and cardiology textbooks in
the United States and United Kingdom. Nevertheless,
even in the English speaking world, large numbers of
people receive treatment for low blood pressure;
one Canadian survey found that nearly a tenth of a
community sample was receiving treatment for "low
blood pressure. "I
What is the evidence? At the beginning of this
century most authorities assumed that low blood
pressure was associated with several so called "neuras-
thenic" symptoms, such as tiredness, weakness,
fainting, and dizziness,67 although the same symptoms
were also attributed to high blood pressure.' However,
scepticism increased, culminating in Robinson's
definitive article on the topic in 194O.9 He vehemently
attacked those who regarded low blood pressure as
pathological and presented data showing that low
blood pressure was associated with decreased mortality.
He continued, "the symptoms usually ascribed to
hypotension are in reality commoner among hyper-
tensive persons. There are no symptoms peculiar to
low blood pressure." This rapidly became the new
conventional wisdom. A leading text now states:
"Most persons with systolic pressures in the range of90
to 110 mm Hg are normal and may actually have a
greater life expectancy than those with 'normal'
pressures."'° Although the evidence is, however,
unequivocal that low blood pressure is associated with
decreased mortality" (the exception being the associa-
tion between very low pressures and increased mortality
in subjects with ischaemic heart disease, the so called J
curve relation'2), few data on the morbidity of low
blood pressure exist. For example, although discussing
mortality and morbidity, Robinson presented data
only on mortality.9
Pemberton's analyses on data from an Australian
survey, which disclosed a relation between tiredness
and low blood pressure in women,' reopened the
debate. The relation did not extend to either dizziness
or fainting, symptoms also traditionally associated
with low blood pressure, whereas palpitations showed
an opposite trend, being more common with higher
blood pressures. Pemberton could quote only crude
rates. Blood pressure and tiredness are influenced by
many variables so it is necessary to determine whether
his findings may not only be replicated but also be
explained by confounding. We present an analysis of
data from the health and lifestyle survey," which
provides an opportunity to answer these questions.
Methods
HEALTH AND LIFESTYLE SURVEY
The health and lifestyle survey is the most compre-
hensive population based health survey carried out in
Britain to date. The sampling frame for the survey was
the entire adult population of England, Wales, and
Scotland aged 18 and over. Preliminary selection was
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